These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22305186)

  • 1. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis.
    Mazereeuw G; Lanctôt KL; Chau SA; Swardfager W; Herrmann N
    Neurobiol Aging; 2012 Jul; 33(7):1482.e17-29. PubMed ID: 22305186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.
    Geleijnse JM; Giltay EJ; Kromhout D
    Alzheimers Dement; 2012 Jul; 8(4):278-87. PubMed ID: 21967845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
    Arendash GW; Jensen MT; Salem N; Hussein N; Cracchiolo J; Dickson A; Leighty R; Potter H
    Neuroscience; 2007 Oct; 149(2):286-302. PubMed ID: 17904756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
    Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
    Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnestic subgroup.
    Jacova C; Peters KR; Beattie BL; Wong E; Riddehough A; Foti D; Scheltens P; Li DK; Feldman HH
    Dement Geriatr Cogn Disord; 2008; 25(3):238-47. PubMed ID: 18264009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower omega-3 fatty acid intake and status are associated with poorer cognitive function in older age: A comparison of individuals with and without cognitive impairment and Alzheimer's disease.
    Phillips MA; Childs CE; Calder PC; Rogers PJ
    Nutr Neurosci; 2012 Nov; 15(6):271-7. PubMed ID: 22824373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.
    Smits LL; Pijnenburg YA; Koedam EL; van der Vlies AE; Reuling IE; Koene T; Teunissen CE; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2012; 30(1):101-8. PubMed ID: 22366769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.
    Eriksdotter M; Vedin I; Falahati F; Freund-Levi Y; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Cederholm T; Palmblad J
    J Alzheimers Dis; 2015; 48(3):805-12. PubMed ID: 26402079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term nutraceutical and dietary supplement use on cognition in the elderly: a 10-year systematic review of randomised controlled trials.
    D'Cunha NM; Georgousopoulou EN; Dadigamuwage L; Kellett J; Panagiotakos DB; Thomas J; McKune AJ; Mellor DD; Naumovski N
    Br J Nutr; 2018 Feb; 119(3):280-298. PubMed ID: 29310724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
    Kavanagh S; Van Baelen B; Schäuble B
    J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis.
    Hooijmans CR; Pasker-de Jong PC; de Vries RB; Ritskes-Hoitinga M
    J Alzheimers Dis; 2012; 28(1):191-209. PubMed ID: 22002791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.